Abstract
Joint models for survival and longitudinal data have recently become quite popular in cancer and AIDS clinical trials, where a longitudinal biologic marker such as CD4 count or immune response can be an important predictor of survival. Often in clinical trials where the primary endpoint is time to an event, patients are also monitored longitudinally with respect to one or more biologic endpoints throughout the follow-up period. This may be done by taking immunologic or virologic measures in the case of infectious diseases or perhaps with a questionnaire assessing the quality of life after receiving a particular treatment. Often these longitudinal measures are incomplete or may be prone to measurement error. These measurements are also important because they may be predictive of survival. Therefore methods which can model both the longitudinal and the survival components jointly are becoming increasingly essential in most cancer and AIDS clinical trials.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ibrahim, J.G., Chen, MH., Sinha, D. (2001). Joint Models for Longitudinal and Survival Data. In: Bayesian Survival Analysis. Springer Series in Statistics. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-3447-8_7
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3447-8_7
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-2933-4
Online ISBN: 978-1-4757-3447-8
eBook Packages: Springer Book Archive